Bad bug, no drugs: The real end of antibiotics?
By health.harvard.edu
In September 2016, a woman in her 70s died of septic shock in Reno, Nevada, from an infection which was fully resistant to 26 different antibiotics. She had spent much of the previous two years in India, where she was treated for a hip fracture. The hip became infected, and after several more hospital stays, she returned to her home in Nevada.
Within weeks, she was desperately ill, and back in a hospital in Reno. A sample from her hip wound revealed a strain of the bacteria Klebsiella pneumoniae which was not sensitive to any antibiotics. It was even resistant to a drug called colistin, an old-fashioned, somewhat toxic, and rarely used antibiotic that is considered the last line of defense against antibiotic-resistant bacteria. Before she died, the patient was isolated and kept in a private room. There is no indication that her resistant bacteria had spread to other patients in the hospital or in the Reno area.
How these bacteria outsmart antibiotics
The Klebsiella bacteria that killed her had a powerful enzyme that breaks down antibiotics, known as New Dehli metallo-beta-lactamase (NDM), because it was first found in a patient who had travelled to that Indian city. Indian politicians have disputed the link between their capital and a deadly superbug, and the local tourism board and chamber of commerce probably aren’t too thrilled about it either. In any case, it is probably unfair to focus too much on the Indian origin of this resistant bacteria. Klebsiella bacteria with a slightly different, but equally fearsome form of antibiotic resistance known as KPC have already become entrenched in the United States, as well as in Brazil, China, Israel, Colombia, and Italy.
The vast majority of cases of resistant Klebsiella infection in the United States involve patients who have been hospitalized. But alarmingly, highly resistant bacteria have started to percolate down into the community. A recent outbreak of NDM-positive Klebsiella in Colorado involved patients without health care exposures. A woman in Pennsylvania presented to a clinic in May 2016 with a urinary tract infection with bacteria resistant to colistin, which she had probably picked up during a recent hospital stay.
Is it the end of antibiotics as we know them?
Hand-wringing about antibiotic resistance has been around almost as long as antibiotics. Newsweek somewhat prematurely proclaimed “The End of Antibiotics” in 1994, and the New England Journal of Medicine bewailed the rising tide of antibiotic resistance as early as 1960. All the way back in 1945, scientists had discovered it was relatively easy to create antibiotic-resistant bacteria by exposing them to very small amounts of antibiotics, and then gradually increasing their degree of antibiotic exposure. In retrospect, this shouldn’t be so surprising. Penicillin and cephalosporin antibiotics are derived from molds, which used these compounds for millennia to suppress competition from bacteria. So bacteria, in turn, have developed ways to neutralize and break down antibiotics. Overuse of antibiotics has favored the spread of bacteria carrying these resistance mechanisms.
Another sobering development is that the antibiotic pipeline is drying up, with dim prospects of new drugs coming along to replace the old ones that are losing potency. The economics of antibiotic discovery are bad. Many pharmaceutical corporations have gotten out of the business of developing new antibiotics altogether. The cost of bringing new drugs to market can ratchet up into the billions. The anticipated payoffs are small, as infectious diseases practitioners only use new and powerful antibiotics when absolutely necessary, in an effort to have them retain their effectiveness for as long as possible.
Here’s what you can do
You can take a number of steps as a patient, a consumer, and a citizen to help keep the flood waters of antibiotic resistance from breaking through the levee.
Don’t press your doctor to prescribe antibiotics if they believe it is unnecessary. Taking antibiotics increases your risk of acquiring drug-resistant bacteria, kills off your beneficial gut bacteria, known as your “microbiome,” and exposes you to the potentially deadly bowel infection, Clostridium difficile colitis.
About 80% of the antibiotic use in the United States is in agriculture, not medicine. In particular, low doses of antibiotics are added to livestock feed in factory farms to prevent infections and promote growth. This constant, low-level antibiotic exposure is an excellent way to create drug-resistant bacteria. At least some of these bacteria probably work their way up the food chain to affect humans. You can support the responsible use of antibiotics in agriculture by only purchasing meat raised without antibiotics. And consider calling your congressperson to ask their support for greater public funding for new antibiotic discovery.
And while this sounds bleak, there are other things you can do as a consumer and as a patient to help. You can start by paying attention to the food you eat and by not pressing your doctor for unnecessary antibiotics.
Source: http://www.health.harvard.edu/blog/bad-bug-no-drugs-real-end-antibiotics-2017022711103
Wednesday, May 6, 2026
Trileptal For Depression: A Patient Guide
Depression is a condition that affects a significant number of people and can range from mild and occasional to persistent and severely disruptive. Understanding the available treatment options is an important part of managing symptoms effectively. Healthcare providers evaluate the severity of the condition and the patient's overall health profile before recommending a specific medication or combination of treatments. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by sudden, abnormal electrical activity in the brain. Seizures vary widely in their manifestation, from brief lapses in consciousness lasting only seconds to full convulsive episodes involving the entire body. The specific seizure type, the region of the brain involved, and the underlying cause of the epilepsy are all important factors in determining the most appropriate treatment approach. Trileptal (oxcarbazepine) belongs to the class of medications used for seizure and epilepsy treatment and is commonly considered by clinicians evaluating treatment options for this condition. Patients looking closely at trileptal for depression will find that the medication offers a practical option for many individuals dealing with this specific issue, particularly when first-line approaches have provided incomplete relief. As with any prescription or over-the-counter medication, proper dosing and adherence to usage guidelines are essential to getting the most benefit from Trileptal while minimizing the risk of side effects. Taking the medication as directed, at the appropriate time of day, and for the full recommended duration helps ensure therapeutic blood levels are maintained. Patients should inform their healthcare provider of all other medications they are taking to check for potential interactions. For broader context on treatment options related to seizure and epilepsy treatment, seizure and epilepsy treatment provides evidence-based information covering the full range of medications used in this therapeutic area, helping patients and caregivers compare approaches and make informed decisions alongside their medical team.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.